The statistical results showed that the proportions of CD3+, CD8+ and CD20+ TILs were significantly different between the KRAS+ and ALK+ and EGFR+ NSCLC groups, and the proportion was higher in KRAS+ NSCLC patients (all p < 0.05, Figures 2K, M, P). Here, KRAS is linked to non-small cell lung carcinoma.